Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
Jump to:
Id | http://purl.obolibrary.org/obo/NCIT_C65475
http://purl.obolibrary.org/obo/NCIT_C65475
|
---|---|
Preferred Name | Doxepin |
Definitions |
A dibenzoxepin derivative and tricyclic antidepressant (TCA) with antipruritic, antidepressive and anxiolytic activities. Doxepin blocks the reuptake of norepinephrine and serotonin (5-HT) into presynaptic terminals thereby prolonging the availability of the monoaminergic neurotransmitters within the synaptic cleft and enhancing their neurotransmission. Doxepin also has antagonistic effects on histamine H1, 5-HT2, alpha-1 adrenergic, and muscarinic receptors. The antipruritic effect of this agent is mediated through inhibition of histamine receptors.
|
Type | http://www.w3.org/2002/07/owl#Class |
All Properties
definition | A dibenzoxepin derivative and tricyclic antidepressant (TCA) with antipruritic, antidepressive and anxiolytic activities. Doxepin blocks the reuptake of norepinephrine and serotonin (5-HT) into presynaptic terminals thereby prolonging the availability of the monoaminergic neurotransmitters within the synaptic cleft and enhancing their neurotransmission. Doxepin also has antagonistic effects on histamine H1, 5-HT2, alpha-1 adrenergic, and muscarinic receptors. The antipruritic effect of this agent is mediated through inhibition of histamine receptors. |
---|---|
label |
Doxepin
|
prefLabel |
Doxepin
|
Legacy Concept Name |
Doxepin
|
in_subset | |
Preferred_Name |
Doxepin
|
UMLS_CUI |
C0013085
|
FDA_UNII_Code |
5ASJ6HUZ7D
|
prefixIRI |
NCIT:C65475
|
Accepted_Therapeutic_Use_For |
Insomnia
|
Contributing_Source |
FDA
|
subClassOf | |
CHEBI_ID |
CHEBI:4710
|
Has_Salt_Form | |
code |
C65475
|
type | |
Semantic_Type |
Pharmacologic Substance
|
CAS_Registry |
1668-19-5
|
Add comment
Delete | Subject | Author | Type | Created |
---|---|---|---|---|
No notes to display |